Intensification treatment based on early FDG‐PET in patients with high‐risk diffuse large B‐cell lymphoma: a phase II GELTAMO trial

No abstract is available for this paper.

• Publication year

  2014

• Venue

  British Journal of Haematology

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.13036PMID 25066542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.

  2013cited by this paper
• patients enrolled in the GIMEMA LAL 0496 protocol presentation and correlation with response to induction treatment in Adult T-cell acute lymphoblastic leukemia: biologic profile at

  2013cited by this paper
• Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab.

  2012cited by this paper
• Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

  2012cited by this paper
• Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

  2011cited by this paper
• 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation

  2011cited by this paper
• CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

  2011cited by this paper
• Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

  2011cited by this paper
• SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

  2011cited by this paper
• Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

  2010cited by this paper
• Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

  2010cited by this paper
• Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

  2010cited by this paper
• Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

  2010cited by this paper
• Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre‐transplant FDG‐PET scan following salvage chemotherapy

  2010cited by this paper
• Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

  2010cited by this paper
• Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

  2009cited by this paper
• Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

  2009cited by this paper
• High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.

  2009influential reference
• Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials

  2009cited by this paper
• Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

  2009cited by this paper
• Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation – where do we stand?

  2009cited by this paper
• Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

  2009cited by this paper
• High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.

  2008cited by this paper
• Dose‐escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem‐cell transplantation in poor‐risk aggressive B‐cell lymphoma: a prospective study from the GEL–TAMO Study Group

  2008cited by this paper
• R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

  2008cited by this paper
• Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

  2008cited by this paper
• Prognostic Value of Positron Emission Tomography (PET) Scan in Patients with Relapsed Hodgkin Lymphoma or Aggressive Non-Hodgkin Lymphoma Receiving Salvage Chemotherapy Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

  2007cited by this paper
• Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

  2007cited by this paper
• The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma.

  2006cited by this paper
• 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

  2006cited by this paper
• Clinical Trials and Observations

  2005cited by this paper
• FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

  2005influential reference
• [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

  2005cited by this paper
• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

  2005cited by this paper
• FDG-PET/CT in re-staging of patients with lymphoma

  2004cited by this paper
• High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.

  2003cited by this paper
• High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis.

  2003cited by this paper
• Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

  2003cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

  2001cited by this paper
• BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors

  1997cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper

• Prognostic Value of Interim [18F]FDG PET in Large B-Cell Lymphoma: A Systematic Review and Meta-analysis with a Particular Focus on Interim Deauville Score 5 Disease.

  2026cites this paper
• Could treatment modification based on early response assessment improve results in DLBCL?

  2025cites this paper
• Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement

  2024cites this paper
• Application of interim PET-CT in first-line treatment decision-making for lymphoma

  2023cites this paper
• 增强剂量免疫化疗联合一线自体外周血造血干细胞移植治疗年轻、高危侵袭性B细胞淋巴瘤疗效及预后因素分析

  2022cites this paper
• PET/CT in Hodgkin Lymphoma: An Update.

  2022cites this paper
• PET/CT in Non-Hodgkin Lymphoma: An Update.

  2022cites this paper
• Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma

  2022cites this paper
• Predicting primary treatment failure using interim FDG‐PET scanning in diffuse large B‐cell lymphoma

  2021cites this paper
• The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma.

  2021cites this paper
• PET imaging of lymphomas

  2021cites this paper
• Diffuse large B‐cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

  2021cites this paper
• PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.

  2021cites this paper
• The optimal use of PET/CT in the management of lymphoma patients.

  2021cites this paper
• The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma.

  2021cites this paper
• Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update

  2021cites this paper
• The 18F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea).

  2021cites this paper
• The 18 F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autologo de Médula Ósea)

  2020cites this paper
• FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study

  2020cites this paper
• Evolving Role of PET-Based Novel Quantitative Techniques in the Management of Hematological Malignancies.

  2019cites this paper
• The Role of 18 FDG-PET/CT in Malignant Lymphomas: Clinical Implications

  2018cites this paper
• Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

  2018cites this paper
• Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.

  2018cites this paper
• FDG‐PET/CT in the management of lymphomas: current status and future directions

  2018cites this paper
• Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma

  2018cites this paper
• PET/MRI in Lymphoma

  2018cites this paper
• Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?

  2018cites this paper
• 18F-FDG PET/CT in the clinical management of patients with lymphoma

  2017cites this paper
• Association between textural and morphological tumor indices on baseline PET‐CT and early metabolic response on interim PET‐CT in bulky malignant lymphomas

  2017cites this paper
• Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

  2017cites this paper
• An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.

  2017cites this paper
• Validation of the NCCN‐IPI for diffuse large B‐cell lymphoma (DLBCL): the addition of β2‐microglobulin yields a more accurate GELTAMO‐IPI

  2017cites this paper
• 18F-FDG PET/CT in the clinical management of patients with lymphoma.

  2017cites this paper
• Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas

  2016cites this paper
• PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas

  2016cites this paper
• Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.

  2016cites this paper
• The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials

  2016cites this paper
• Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?

  2016cites this paper
• FDG PET/CT response in diffuse large B-cell lymphoma

  2016cites this paper
• To PET or Not to PET: Interim Imaging in DLBCL

  2016cites this paper
• FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

  2016cites this paper
• FDG-PET(CT)-adapted trials in non-Hodgkin lymphoma

  2015cites this paper
• PET/CT: appropriate application in lymphoma.

  2014cites this paper
• Imaging in Clinical Oncology

  2014cites this paper